Skip to main content

Table 10 Total economic benefits of influenza immunisation to the school-age population

From: Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children

Influenza-associated costs

No influenza immunisation

Influenza immunisation

Costs avoided

Direct costs

 Laboratory diagnosis

259,878,840

246,608,193

13,270,647

 Medical consultations

266,216,669

251,638,144

14,578,525

 Drugs

43,978,880

41,388,986

2,589,893

 Hospitalisations

1,866,950,845

1,773,439,651

93,511,195

 Influenza immunisation to school-aged population

 

27,421,602

−27,421,602

Total direct costs (third-party payer perspective)

2,437,025,233

2,340,496,577

96,528,657

Indirect costs

 Productivity loss

267,469,325

253,037,896

14,431,429

 Premature death

29,368,240

28,338,858

1,029,382

 Total indirect costs

296,837,565

281,376,755

15,460,811

Total costs of influenza (societal perspective)

2,733,862,799

2,621,873,331

111,989,467

  1. All costs are in USD